Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT05950945
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
250 Enrollment(s)
54 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
RECRUITING
NCT05417594
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
490 Enrollment(s)
31 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Solid Malignancies
SUSPENDED
NCT04585958
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer
55 Enrollment(s)
4 Study location(s)
INTERVENTIONAL (PHASE1)
Endometrial Serous Adenocarcinoma


Metastatic Malignant Solid Neoplasm


Unresectable Malignant Solid Neoplasm
ACTIVE_NOT_RECRUITING
NCT03334617
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
531 Enrollment(s)
46 Study location(s)
INTERVENTIONAL (PHASE2)
Non-Small Cell Lung Cancer
RECRUITING
NCT04047641
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
80 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Acute Myeloid Leukemia


Blasts 20 Percent or More of Bone Marrow Nucleated Cells


High Risk Myelodysplastic Syndrome


Recurrent Acute Biphenotypic Leukemia


Recurrent Acute Myeloid Leukemia


Recurrent High Risk Myelodysplastic Syndrome


Refractory Acute Myeloid Leukemia


Refractory High Risk Myelodysplastic Syndrome
RECRUITING
NCT04686305
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
244 Enrollment(s)
80 Study location(s)
INTERVENTIONAL (PHASE1)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING
NCT04482309
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
468 Enrollment(s)
123 Study location(s)
INTERVENTIONAL (PHASE2)
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer


Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
NOT_YET_RECRUITING
NCT06731803
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
36 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Esophagogastric Adenocarcinoma